$TRLV

Simply Wall St says Trulieve Cannabis (NYSE: TRLV) reported Q2 2026 sales of $271.0M, down from $302.1M, while net loss widened to $406.0M. Loss per share from continuing operations rose to $2.10 from $0.07. For 1H 2026, sales fell to $557.7M and net loss to $403.6M. The piece discusses how federal rescheduling, costs, and a $50M buyback authorization could affect the investment outlook.

Trulieve Cannabis Corp. (NYSE: TRLV) reported Q2 2026 revenue of $271 million and 60% gross margin, with 94% of revenue from retail sales. GAAP net loss attributable to common shareholders was $406 million, including a $407 million impact from Harvest deconsolidation. Adjusted net income was $20 million. Cash flow from operations was $109 million and free cash flow $74 million for the first half. The company also announced a share repurchase program.

Trulieve Cannabis (TRLV) shares rose 5.6% premarket to $9.50 after it reported Q2 2026 results before the open. The quarter was the first full period under federal rescheduling of state-legal medical cannabis from Schedule I to III, removing 280E tax for qualifying operators, according to the DOJ and DEA. Analysts expected about $0.08 EPS on ~$272M revenue, and seven analysts rated TRLV Buy-equivalent with an average $18.71 target.

Trulieve Cannabis Corp. (TRLV) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.1 2 exhibit991trlvearningsrele.htm EX-99.1 Document Exhibit 99.1 Trulieve Reports Second Quarter 2026 Results • Second quarter revenue of $271 million, with 60% gross margin • Cash flow from operations of $109 million and free cash flow of $74 million* in first half of 2026

Trulieve Cannabis Corp. (TRLV) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. tcnnf-20260805 false 0001754195 0001754195 2026-08-05 2026-08-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM 8-K ___________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of

A roundup of Monday analyst actions includes Morgan Stanley reiterating Nvidia (overweight) and Broadcom (overweight), with a focus on data center memory-cycle signals. BMO downgraded Charles Schwab to market perform. Cantor reiterated Tesla overweight ahead of earnings. Other calls include price targets for Versigent, Crane, Lumentum, and Apple, plus initiations for BP and TotalEnergies.

Trulieve Cannabis Corp. (NYSE: TRLV) said it will open a new medical cannabis dispensary in Marco Island, Florida, at 615 E Elkcam Circle. The grand opening is scheduled for July 24, with walk-in and express pickup. The store will offer Trulieve in-house and partner brands, and Trulieve noted delivery and discounts for Florida customers.

Motley Fool compares Trulieve Cannabis (NYSE: TRLV) and Vireo Growth (OTC: VREOF). Trulieve deconsolidated adult-use dispensaries into Harvest to qualify for NYSE listing, reporting Q1 revenue of $287M (-4% YoY) and EPS $0.02. Vireo reported Q1 revenue $106.2M (+333.5% YoY) and EPS loss $0.02, after acquisitions including Schwazze, Eaze, and Hawthorne.

Trulieve Cannabis Corp. (TCNNF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. tcnnf-20260630 false 0001754195 0001754195 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM 8-K ___________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of

The DEA began an expedited hearing on June 29 on whether to move marijuana from Schedule I to Schedule III, with a July 15 conclusion deadline, according to Forbes and Ropes & Gray. An April 23 order already reclassified certain medical cannabis to Schedule III, per Cannabis Business Times. The AdvisorShares Pure US Cannabis ETF MSOS and holdings like Trulieve (TRLV) are highlighted ahead of DOJ’s July 2 response.